VistaGen Therapeutics (VTGN) Q1 2027 earnings summary

Executive summary

• Reported fiscal Q1 2027 results with a focus on advancing fasedienol for social anxiety disorder and strategic corporate updates.

• Preliminary data from PALISADE-3 and PALISADE-4 studies showed nominally significant efficacy signals in very severe social anxiety subgroups, with favorable safety and tolerability.

• FDA engagement planned for potential Phase 3 path forward for fasedienol.

• Leadership strengthened with appointments of a new Chief Medical Officer and Board member with neuroscience expertise.

Financial highlights

• Revenue for the quarter was $1.5 million, primarily from the expiration of an exclusivity agreement, compared to $0.2 million in the prior year.

• Research and development expense was $10.9 million, down from $11.7 million year-over-year.

• General and administrative expense was $3.9 million, down from $4.4 million year-over-year.

• Net loss was $13.0 million, an improvement from $15.1 million in the same quarter last year.

• Cash, cash equivalents, and marketable securities totaled $31.7 million as of June 30, 2026.

Outlook and guidance

• Cash runway expected to fund operations into 2027, but not for more than a year from the reporting date.

• R&D expenses anticipated to decrease due to cash preservation and completion of key studies; future trends depend on FDA feedback.

• G&A expenses expected to remain stable, contingent on regulatory developments.